In HCC, POLD1 overexpression, often driven by TP53 mutations, correlates with advanced staging, vascular invasion, and poor survival, suggesting a tumor-promoting role resistant to conventional therapies (22). Here, TP53 is linked to hepatocellular carcinoma.